JPWO2020010118A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020010118A5 JPWO2020010118A5 JP2020573365A JP2020573365A JPWO2020010118A5 JP WO2020010118 A5 JPWO2020010118 A5 JP WO2020010118A5 JP 2020573365 A JP2020573365 A JP 2020573365A JP 2020573365 A JP2020573365 A JP 2020573365A JP WO2020010118 A5 JPWO2020010118 A5 JP WO2020010118A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- syndrome
- disease
- aryl
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 38
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims description 36
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims description 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 36
- 208000011580 syndromic disease Diseases 0.000 claims description 35
- 239000005557 antagonist Substances 0.000 claims description 32
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 27
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000001363 autoimmune Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 206010047115 Vasculitis Diseases 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 229960002964 adalimumab Drugs 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 206010014599 encephalitis Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 229960000403 etanercept Drugs 0.000 claims description 5
- 229960001743 golimumab Drugs 0.000 claims description 5
- 229960000598 infliximab Drugs 0.000 claims description 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010015150 Erythema Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000031951 Primary immunodeficiency Diseases 0.000 claims description 4
- 201000002661 Spondylitis Diseases 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 208000007784 diverticulitis Diseases 0.000 claims description 4
- 231100000321 erythema Toxicity 0.000 claims description 4
- -1 hydroxy, hydroxymethyl Chemical group 0.000 claims description 4
- 208000028774 intestinal disease Diseases 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010003267 Arthritis reactive Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000010007 Cogan syndrome Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 208000004332 Evans syndrome Diseases 0.000 claims description 2
- 208000028387 Felty syndrome Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000034619 Gingival inflammation Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims description 2
- 208000029400 Inclusion myopathy Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
- 208000012309 Linear IgA disease Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 206010058143 Lupus vasculitis Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010029379 Neutrophilia Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010053869 POEMS syndrome Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000006311 Pyoderma Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 206010042276 Subacute endocarditis Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000026928 Turner syndrome Diseases 0.000 claims description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000032159 Vaginal inflammation Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 108010011562 aspartic acid receptor Proteins 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 2
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims description 2
- 206010071578 autoimmune retinopathy Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000004559 cerebral degeneration Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 208000006881 esophagitis Diseases 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000002741 leukoplakia Diseases 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 201000003265 lymphadenitis Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000029081 mast cell activation syndrome Diseases 0.000 claims description 2
- 208000008275 microscopic colitis Diseases 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000002232 neuromuscular Effects 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 235000021395 porridge Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000016905 Hashimoto encephalopathy Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000021866 Dressler syndrome Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000021330 IgG4-related disease Diseases 0.000 claims 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010064921 Urinary tract inflammation Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 108090000426 Caspase-1 Proteins 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 229960003115 certolizumab pegol Drugs 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101150044782 CARD8 gene Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 101150061038 NLRP3 gene Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693879P | 2018-07-03 | 2018-07-03 | |
| US201862693886P | 2018-07-03 | 2018-07-03 | |
| US62/693,879 | 2018-07-03 | ||
| US62/693,886 | 2018-07-03 | ||
| US201862702602P | 2018-07-24 | 2018-07-24 | |
| US201862702621P | 2018-07-24 | 2018-07-24 | |
| US62/702,621 | 2018-07-24 | ||
| US62/702,602 | 2018-07-24 | ||
| PCT/US2019/040357 WO2020010118A1 (en) | 2018-07-03 | 2019-07-02 | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529780A JP2021529780A (ja) | 2021-11-04 |
| JP2021529780A5 JP2021529780A5 (https=) | 2022-07-11 |
| JPWO2020010118A5 true JPWO2020010118A5 (https=) | 2022-07-11 |
Family
ID=67441657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573365A Pending JP2021529780A (ja) | 2018-07-03 | 2019-07-02 | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220339169A1 (https=) |
| EP (1) | EP3817737A1 (https=) |
| JP (1) | JP2021529780A (https=) |
| KR (1) | KR20210030947A (https=) |
| CN (1) | CN112654350A (https=) |
| AU (1) | AU2019299444A1 (https=) |
| CA (1) | CA3103664A1 (https=) |
| IL (1) | IL279889A (https=) |
| WO (1) | WO2020010118A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210024A (es) | 2018-07-20 | 2021-02-22 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| ES2991366T3 (es) | 2020-05-08 | 2024-12-03 | Halia Therapeutics Inc | Inhibidores de NEK7 cinasa |
| WO2022047758A1 (en) * | 2020-09-05 | 2022-03-10 | Zhejiang University | Genetical disease modelling using mammals having nlrp3 mutation |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| US20250082611A1 (en) * | 2021-07-23 | 2025-03-13 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| JP2024532476A (ja) * | 2021-09-02 | 2024-09-05 | モレキュラー アクシオム エルエルシー | Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法 |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| US20230416412A1 (en) * | 2022-05-31 | 2023-12-28 | Hoffmann-La Roche Inc. | Prevention or mitigation of t-cell engaging agent-related adverse effects |
| EP4561574A1 (en) * | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| CN116459260A (zh) | 2023-04-28 | 2023-07-21 | 中国人民解放军空军军医大学 | 一种特异性靶向nlrp3炎症小体抑制剂的用途 |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| WO2024248286A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 암 치료용 약학 조성물 |
| WO2025068958A1 (en) * | 2023-09-29 | 2025-04-03 | Novartis Ag | Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
| ZA929699B (en) * | 1991-12-20 | 1994-06-14 | Lilly Co Eli | Sulfonimidamides |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| JP2005510542A (ja) * | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| US7749999B2 (en) * | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| US20180008629A1 (en) * | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| WO2017079352A2 (en) * | 2015-11-04 | 2017-05-11 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| WO2017123672A1 (en) * | 2016-01-12 | 2017-07-20 | Lawrence Chan | Combination treatment for inflammatory diseases |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| US11339136B2 (en) * | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| NZ760129A (en) * | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| ES2988798T3 (es) * | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| WO2019166624A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
-
2019
- 2019-07-02 AU AU2019299444A patent/AU2019299444A1/en not_active Abandoned
- 2019-07-02 EP EP19745415.0A patent/EP3817737A1/en not_active Withdrawn
- 2019-07-02 US US17/252,630 patent/US20220339169A1/en not_active Abandoned
- 2019-07-02 WO PCT/US2019/040357 patent/WO2020010118A1/en not_active Ceased
- 2019-07-02 KR KR1020217003092A patent/KR20210030947A/ko not_active Withdrawn
- 2019-07-02 CN CN201980052145.7A patent/CN112654350A/zh active Pending
- 2019-07-02 JP JP2020573365A patent/JP2021529780A/ja active Pending
- 2019-07-02 CA CA3103664A patent/CA3103664A1/en not_active Abandoned
-
2020
- 2020-12-30 IL IL279889A patent/IL279889A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020010118A5 (https=) | ||
| JP2021529780A5 (https=) | ||
| US11992481B2 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
| JP2021529780A (ja) | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 | |
| JP6419076B2 (ja) | Ｒｈｏキナーゼ阻害剤 | |
| JP6639497B2 (ja) | ブロモドメインインヒビターおよびその使用 | |
| CN105611933B (zh) | 抗增生性化合物 | |
| KR20240014585A (ko) | 악성 종양 치료용 제제 및 조성물 | |
| JP2010526883A (ja) | 皮膚潰瘍の治療方法 | |
| HUE026323T2 (en) | Imidazopyridazines as akt kinase inhibitors | |
| Suraya et al. | Molecular mechanism of asthma and its novel molecular target therapeutic agent | |
| WO2019046697A1 (en) | COMPOSITIONS AND METHODS FOR TREATING ALCOHOLIC HEPATIC DISEASE, ALCOHOL INDUCED BRAIN DENSILE AND REDUCING ALCOHOL DEPENDENCE | |
| US20090247558A1 (en) | Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases | |
| JP7731151B2 (ja) | トリアゾロピラジン系化合物及びその用途 | |
| WO2021002887A1 (en) | Gut-targeted nlrp3 antagonists and their use in therapy | |
| CN106146482B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
| JP2025516002A (ja) | ピリミジノン含有１７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤 | |
| CN119233975A (zh) | 新型化合物及其用于治疗自身免疫性疾病的用途 | |
| CN104341416A (zh) | 蛋白酪氨酸激酶抑制剂及其应用 | |
| JP2024509587A (ja) | Ｊａｋ媒介性障害の治療に使用するためのｌｏｒｐｕｃｉｔｉｎｉｂ | |
| Leung et al. | The many faces of Kawasaki syndrome | |
| CA3155838C (en) | Novel compound and use thereof in treating autoimmune diseases | |
| WO2020077120A1 (en) | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | |
| WO2024193509A1 (zh) | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 | |
| Sun et al. | Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold |